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Objective: Psoriatic arthritis mutilans (PAM) is the most severe phenotype of psoriatic
arthritis due to excessive bone erosion causing joint destruction and decreased functional
capacity. The aim of this study was to investigate the prevalence of comorbidities among
patients with PAM and the association between comorbidities and joint involvement.
Methods: A total of 66 patients aged ≥18 years from the Nordic countries with past or
present psoriasis alongwith at least onemutilated joint were included in the present study.
Results: The median number of comorbid conditions per patient was 1 [interquartile
range (IQR) 0–2] and 16.7% reported three or more comorbidities. The most frequent
comorbidity was hypertension (36.4%). Themedian number of mutilated joints per patient
was 3 (IQR 1–8.3; range 1–38).
Conclusion: Two thirds of the patients with PAM reported comorbid conditions and
the most frequent was hypertension which affected more than a third of the patients.
However, this study was unable to detect any association between comorbidities and
the severity of PAM.
Keywords: psoriasis, arthritis, mutilans, comorbidity, multinational study
INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease affecting 20–30% of patients
with psoriasis (1–3). In the majority of patients with PsA, skin affection precedes arthritis by several
years (4). PsA is characterized by synovial and entheseal inflammation along with extraarticular
manifestations, such as nail lesions and uveitis (4, 5). Variable clinical presentations have given
rise to five PsA subtypes: arthritis in the distal interphalangeal joints, asymmetric oligoarthritis,
symmetric polyarthritis, axial spondyloarthritis, and psoriatic arthritis mutilans (PAM) (6). Any of
these subtypes may be present in different combinations and the disease pattern may change over
time (4, 7).
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PAM is the most severe clinical subtype of PsA and is
characterized by digital telescoping termed “opera-glass finger,”
resulting in loss of function of the affected joint (6). The study
of PAM has been impeded by the lack of internationally accepted
classification criteria. However, attempts have beenmade in order
to define PAM (8). Due to inconsistent classification criteria,
reports on the prevalence of PAM vary widely with estimates
ranging from 0.6 to 21% among patients with PsA (4, 6, 9–
13). Meanwhile, the Nordic PAM Study reported a prevalence
of nearly four cases per million inhabitants in the Nordic
population (14). However, arthritis mutilans, may also occur
along with rheumatoid arthritis, chronic reactive arthritis, and
juvenile arthritis (15). Most previous reports of PAM are serial
case reports and only few reports have included more than ten
patients (3, 14, 16–19).
The pathogenesis of the different PsA phenotypes is still
not fully understood. Genetic factors associated with psoriatic
disease have become more clearly defined and may contribute to
our understanding of the different clinical presentations of PsA
(5, 20). Moreover, psoriatic disease is associated with a number
of comorbidities. For example, metabolic syndrome is more
prominent in patients with PsA than in the general population
(21, 22). Also, the risk of cardiovascular disease (CVD) is
increased among patients with PsA (22, 23). Shared inflammatory
pathways, proinflammatory cytokine release and adhesion
molecule expression may contribute to this association. Tumor
necrosis factor (TNF)-α has been associated with endothelial
dysfunction, and interleukin (IL)-17A has been associated
with increased expression of adhesion and pro-inflammatory
molecules associated with CVD (24, 25). Furthermore, it is
well-established that the risk of mental comorbidities, such as
depression and anxiety is higher among patients with psoriasis
than in the general population (26–28). This may, in part, be
caused by the psychosocial difficulties associated with having
psoriasis but may also be related to overlapping mechanisms.
The level of the proinflammatory cytokines IL-1 and IL-6 are
increased in patients with both PsA and depression, indicating
involvement of the same inflammatory process in both diseases
(26). In addition, other inflammatory disorders, such as chronic
obstructive pulmonary disease (COPD) and inflammatory bowel
disease (IBD) are more prevalent among patients with PsA than
among the general population (29–32).
Given its severe rheumatic manifestation, PAM may be
associated with a higher inflammatory burden than other PsA
phenotypes. The aim of this study was to investigate the
prevalence of comorbidities among patients with PAM in the
Nordic PAM Study and to explore the association between these
comorbidities and joint involvement.
METHODS
Patients were identified as part of The Nordic PAM Study
initiated in 2009 to investigate PAM in the Nordic countries. Data
collection has previously been described in detail (14, 17, 33–
35). The study included patients fromDenmark, Iceland, Norway
and Sweden. Patients were identified in collaboration with
specialist societies of dermatology and rheumatology and patient
associations in each country. Included patients met the following
inclusion criteria: (I) able and willing to give written informed
consent; (II) age ≥18 years; (III) past or present psoriasis (skin
or nails) diagnosed by a dermatologist; (IV) presence of clinical
arthritis of the PAM type verified by a rheumatologist; and
(V) radiological findings of severe erosive arthritis, e.g., pencil-
in-cup or gross osteolysis of the bones. Patients meeting any
classification criteria for any other rheumatic joint disease were
excluded from the study. At present 70 patients have been
included in the study. However, four patients were excluded
from the present analysis due to missing information on joint
involvement, leaving a cohort of 66 patients with PAM. The
current inclusion is depicted in Figure 1 (14). The latest patient
was included in April 2014. Cohort characteristics have been
described previously and patient demographics of the present
cohort are presented in Table 1 (14, 33, 35).
Clinical Examination and Data Collection
All patients who met the inclusion criteria underwent clinical
evaluation by board-certified specialists in rheumatology and
dermatology. The extent of joint involvement was assessed
according to the 66/68 American College of Rheumatology
(ACR) joint count for swelling and for tenderness. This joint
count includes both the proximal interphalangeal (PIP) and
the distal interphalangeal (DIP) joints of hands and feet. The
presence of joint deformities, joint mutilation, dactylitis, and
enthesitis was registered. A joint was considered mutilated in
the presence of both clinical manifestation of PAM and joint
destruction characterized by osteolysis on X-ray evaluation.
Joints were radiographed at inclusion if the most recent previous
radiographs had been made more than 3 months prior to
inclusion. X-rays were evaluated by a radiologist and the findings
have been reported elsewhere (34, 35). Information on current
and past history of comorbid medical illness was obtained by
the investigators as part of a semi-structured interview. Listed
comorbidities included cancer, diabetes mellitus, COPD, IBD,
cerebral insult, hypertension, acute myocardial infarct, heart
failure, other autoimmune disease, infectious disease requiring
hospitalization, and others. For each patient, the type, number,
onset date, and potential current symptoms and required
treatment were registered for the reported comorbidities. The
investigators reviewed the patients’ medication list in order to
verify the reported comorbidities.
Data Analysis
All patient data were coded at inclusion. Continuous data
were expressed as mean ± standard deviation (SD) for
normally distributed data, and non-normally distributed data
were expressed as median with interquartile range (IQR).
Normality was assessed by plotting histograms and performing
the D’Agostino-Person normality test. Categorical variables were
analyzed using descriptive statistics and reported as frequency
(n, %). The descriptive statistical analysis was done in Microsoft
Excel 2019. Fischer’s exact test was performed in 2 × 2 tables
to investigate the association between the number of comorbid
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FIGURE 1 | STROBE flowchart of the recruitment and inclusion process.
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Denmark 21 55.14 ± 10.75
(41–75)
10 (48) 11 (52)
Iceland 3 70.67 ± 10.07
(63–83)
3 (100) 0 (0)
Norway 10 52.90 ± 9.96
(44–79)
6 (60) 4 (40)
Sweden 32 60.09 ± 11.18
(42–93)
13 (41) 19 (59)
Total 66 57.91 ± 11.32
(41–93)
32 (48) 34 (52)
conditions and the number of affected joints. This test and the
D’Agostino-Person test were carried out in GraphPad Prism 8.
Ethical Issues
Written informed consent was obtained from all study
participants. The bioethics committee and data protection
authorities of all four countries approved the study protocol.
RESULTS
Joint Involvement
The median number of tender joints per patient was 1 (IQR 0–
7) ranging from 0 to 35, and the median number of swollen
joints per patient was 1 (IQR 0–3) ranging from 0 to 16. The
median number of deformed joints per patient was 0.5 (IQR
0–12.5) ranging from 0 to 59 (Figure 2). In accordance with
the inclusion criteria, all included patients had a minimum of
one mutilated joint. The median number of mutilated joints per
patient was 3 (IQR 1–8.3) ranging from 1 to 38, with 39.4% of
patients presenting five or more and 19.7% presenting ten or
more mutilated joints (Figure 3).
Comorbidities
Comorbid conditions were reported by 65.2% of the participants.
The median number of self-reported comorbid conditions per
patient was 1 (IQR 0–2). A current or past history of two
or more comorbidities was reported by 33.3% of the patients,
and 16.7% reported three or more comorbidities (Figure 4A).
Having two or more comorbidities was equally frequent among
men and women (11:11). The most frequent comorbidity was
hypertension requiring medical treatment (36.4%), followed by
infectious diseases requiring hospitalization (28.8%) and other
autoimmune diseases (12.1%) (Figure 4B).
The most frequently reported infectious diseases requiring
hospitalization were pneumonia (n = 5) and skin infection
due to staphylococci (n = 3). Autoimmune diseases included
thyroid disease (n = 5), uveitis (n = 2), and lung fibrosis (n
= 1). The reported cases of cancer were non-melanoma skin
cancers (n= 2).
Correlation Between Comorbidity and the
Severity of the Joint Disease
Fischer’s exact test was performed to evaluate the probability of
patients having one or more comorbidities in case of one or more
tender joints, swollen joints, or deformed joints. Furthermore,
Fisher’s exact test was used to evaluate the likelihood of patients
having one or more comorbidities in case of more than two
mutilated joints. This test found no correlation between the
number of comorbidities and the number of affected joints
(Supplementary Figures 1–4).
DISCUSSION
The Nordic PAM Study offers a unique opportunity to further
investigate this rare and disabling disease, since this is presently
one of the largest cohorts of patients with PAM worldwide. To
the authors’ knowledge, the present study is the first study to
investigate the prevalence and profile of comorbidities among
patients suffering from PAM. The results are in line with
previously published studies describing the comorbidity profile
among patients with PsA.
Recent studies of comorbidities among patients with PsA
reported a median of two comorbid conditions per patient. More
than a third of these patients had three or more comorbidities
and some patients reported up to 12 comorbid conditions (36,
37). In the present study of patients with PAM, the median
number of self-reported comorbid conditions per patient was one
comorbidity and some patients reported up to six comorbidities.
One third of the patients with PAM reported a current or past
history of two or more comorbidities, and one fifth reported
three or more comorbidities. PsA has an impact on quality of
life, which is directly related to disease activity and structural
damage of the joints. However, increased comorbidity burden
has also been independently associated with decreased functional
capacity. This considered, detection and control of comorbid
conditions among patients with PsA may serve to improve
quality of life in this group of patients (38).
Hypertension is frequent among patients with PsA and similar
to the frequency found among patients with PAM in the present
study (36, 37). This is consistent with other studies suggesting
an increased prevalence of metabolic syndrome among patients
with PsA compared with the general population (21, 22, 39,
40). Frequencies of diabetes mellitus and CVD are also similar
between patients with PAM and patients with PsA in general
(36, 37). Yet, heterogeneity in the definition and categorization of
comorbidities hampers direct comparison between studies. Since
the preparation of the Nordic PAM Study protocol, it has been
well-established that the risk of mental comorbidities, such as
depression and anxiety is higher among patients with psoriatic
disease than among the general population (26–28). These are
some of the most frequent comorbidities among patients with
PsA, affecting approximately one third of the patients (36, 37).
Data on mental illness were not collected in the Nordic PAM
Study, which may very well have contributed to the relatively
low reported number of comorbidities in the Nordic PAM Study.
PAM is the most severe PsA phenotype and seriously affects
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FIGURE 2 | Number of tender, swollen, and deformed joints.
FIGURE 3 | Number of mutilated joints.
social functioning and quality of life. Thus, mental illness may be
expected more frequently among patients with PAM than among
patients suffering from other PsA subtypes (33).
As described initially, many studies have indicated that the
variable clinical presentations of psoriatic disease may be related
to the severity of the inflammatory burden. In this context,
skin severity has been described to be correlated with joint
activity; thus, patients with higher skin severity are two times
more likely to have increased joint involvement (41). Moreover,
comorbid conditions in the form of depression and anxiety
along with hypertension and diabetes mellitus are described
more frequently among patients suffering from both psoriasis
in the skin and PsA than among patients with only psoriasis
in the skin (27, 28). In addition, studies have found that
cardiovascular risk factors are more strongly associated with
severe psoriasis than with mild psoriasis (28, 42). In the
present study, we analyzed the correlation between the severity
of the joint affection and comorbidities by applying Fisher’s
exact test. This test found no association either between the
number of comorbidities and chronic alterations in the form
of mutilated or deformed joints or between the number of
comorbidities and present inflammatory alterations at the time
Frontiers in Medicine | www.frontiersin.org 5 February 2021 | Volume 8 | Article 629741
Mistegård et al. Comorbidities in PAM
FIGURE 4 | Comorbidities among participants in the Nordic PAM study (n = 66). (A) Number of comorbidities per participant. (B) Type of comorbidity. COPD, chronic
obstructive pulmonary disease; IBD, inflammatory bowel disease.
of inclusion in the form of tender or swollen joints. Hence, this
study was unable to confirm the association that other studies
have suggested.
There are still no internationally accepted diagnostic criteria
for this rare variant of PsA. Therefore, an inclusion criterion
in the Nordic PAM Study was the presence of both clinical
manifestation of PAM and confirmation of joint destruction
characterized by osteolysis on X-ray evaluation.
Information on comorbidities was collected by the
investigators as part of a semi-structured interview and
verified through a review of the patients’ medication list.
The investigators registered the type, number, onset date,
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and potential current symptoms and required treatment for
each reported comorbidity. Access to all parts of the patients’
electronic medical file was not permitted in the study protocol.
The use of a semi-structured interview may in this case
have caused underreporting of comorbidities and thereby
underestimation of the number of comorbidities among patients
with PAM.
In conclusion, comorbidities are common among patients
with PAM as two thirds of the participants in the Nordic
PAM Study reported comorbid conditions. The most frequent
comorbidity was hypertension which affected more than
one third of the participants. This knowledge is important
for diagnostic and therapeutic purposes alike, as knowledge
of comorbidities may serve to ensure sufficient treatment
and improved prognosis for patients suffering from PAM.
The present study found no association between severity of
joint affection and number of comorbidities. Future studies
may focus on further evaluation of the significance of the
inflammatory burden in the pathogenesis of the various
PsA phenotypes.
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